Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BEIGENE, LTD.
10/26PRESS RELEASE : Novartis delivers solid Q3 results, with strong growth in Innovative Medic..
DJ
10/21INSIDER SELL : Beigene
MT
10/21BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
PU
10/21BEIGENE : Russia Approves BeiGene's Cancer Medicine for Treatment of Mantle Cell Lymphoma
MT
10/20BEIGENE : Brukinsa Gets Russian Approval to Treat Certain Patients With Mantle Cell Lympho..
MT
10/20BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
BU
10/20Beigene and Nanolek Announce Approval in Russia for Brukinsa? (Zanubrutinib) for Treatm..
CI
10/14BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
10/14BeiGene, Ltd. Provides Contract Update with Celgene Logistics Sàrl
CI
10/13BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA« (Zanubrutinib) fo..
PU
10/12BEIGENE : Bernstein Starts BeiGene at Outperform With $431 Price Target
MT
10/11BEIGENE : Brukinsa Approved in Australia for Mantle Cell Lymphoma
MT
10/10BeiGene Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mant..
CI
10/10BEIGENE : Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mantl..
BU
10/10BEIGENE : Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mantl..
BU
10/08BEIGENE : Drug for Waldenstrom's Macroglobulinemia Wins Regulatory Nod in Australia
MT
10/07BEIGENE : Brukinsa Approved in Australia for Waldenstrom's Macroglobulinemia
MT
10/07BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA« (Zanubrutinib) fo..
BU
10/07Beigene, Ltd. Announces First Regulatory Approval in Australia for Brukinsa for Treatme..
CI
09/24LEAP THERAPEUTICS : Raises $104 Million After Completing Securities Offering; Stock Rises
MT
09/23INSIDER SELL : Beigene
MT
09/21BEIGENE : Added to FTSE Russell Indices
MT
09/20BEIGENE : European commercial team is preparing to launch BRUKINSA, the company's first me..
PU
09/20BeiGene Receives Positive CHMP Opinion for BRUKINSA« (Zanubrutinib) for the Treatment o..
CI
09/20BEIGENE : Wins Positive Opinion from Europe's Drug Regulator for Waldenstrom's Macroglobul..
MT
09/20BEIGENE : Announces Inclusion in FTSE Russell Indices
BU
09/20BEIGENE, LTD.(SEHK : 6160) added to FTSE All-World Index
CI
09/17Asian ADRs Move Lower in Friday Trading
MT
09/17US Futures Modestly Lower Ahead of Fed Meeting Next Week
MT
09/17BEIGENE : Receives Positive Opinion for Brukinsa by European Medicines Agency; Shares Clim..
MT
09/17Top Premarket Gainers
MT
09/17BEIGENE : Receives Positive CHMP Opinion for BRUKINSA« (Zanubrutinib) for the Treatment of..
BU
09/17BeiGene Receives Positive CHMP Opinion for BRUKINSA« (Zanubrutinib) for the Treatment o..
CI
09/17BeiGene Gets CHMP Backing of Brukinsa in Waldenstrom's Macroglobulinemia
DJ
09/16Health Care Stocks Largely Sitting Out Markets Recovery This Afternoon
MT
09/16Health Care Stocks Falling Thursday Afternoon
MT
09/16INSIDER SELL : Beigene
MT
09/16LEAP THERAPEUTICS : Says Additional Data from Mid-Stage Study Show Potential of Cancer Com..
MT
09/16BEIGENE : US FDA Grants BeiGene Accelerated Approval for Marginal Zone Lymphoma Treatment
MT
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
09/15BEIGENE : With its second internally developed medicine filed outside China, BeiGene furth..
PU
09/15Health Care Stocks Edge Higher Premarket Wednesday
MT
09/15BEIGENE : Says US FDA Grants it Accelerated Approval for Brukinsa for Relapsed or Refracto..
MT
09/15BEIGENE : U.S. FDA Grants BRUKINSA« (Zanubrutinib) Accelerated Approval in Relapsed or Ref..
BU
09/15BeiGene, Ltd. announces U.S. Food and Drug Administration Grants Brukinsa Approval in R..
CI
09/14INSIDER BUY : Beigene
MT
09/13Leap Therapeutics Sees Positive Data for Trial of Cancer Treatment
DJ
09/13BEIGENE : US FDA Accepts BeiGene's Biologics License Application for Cancer Drug; Shares J..
MT
09/13BEIGENE : Says US FDA Accepts Biologics License Application for Cancer Drug Tislelizumab
MT
09/13BEIGENE : Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab ..
BU
09/13BeiGene, Ltd. Announces U.S. FDA Acceptance of Biologics License Application for Tislel..
CI
09/12BEIGENE : to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
BU
09/12BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 202..
CI
09/03BEIGENE : Grants Share Options to Four Employees
MT
09/02BEIGENE : This marks the second FDA approval for BRUKINSA and its third approval in Walden..
PU
09/02HANG SENG : Hong Kong Stocks Finish Slightly Higher; BeiGene Rises 5%
MT
09/02BEIGENE : US FDA Approves BeiGene's Cancer Medicine as Treatment for Rare Lymphoma; Shares..
MT
09/01BEIGENE : Brukinsa Gets FDA Nod for Treatment of Waldenstrom's Macroglobulinemia
MT
09/01BEIGENE : U.S. FDA Grants BRUKINSA« (Zanubrutinib) Approval in Waldenström's Macroglobulin..
BU
09/01BeiGene, Ltd. Receives Approval from the U.S. Food and Drug Administration of BRUKINSA«..
CI
08/30Asian ADRs Move Lower in Monday Trading
MT
08/30BEIGENE : H1 Loss Narrows, Revenue Climbs on Increased Income From Products, Collaboration..
MT
08/26HUTCHMED CHINA : BeiGene Start US Clinical Trial of Combination Therapy for Breast Cancer
MT
08/26HUTCHMED CHINA : Doses First Patient in Study of Potential Drug for Breast, Endometrial Ca..
MT
08/26HUTCHMED CHINA : Launches Early-Stage Study of Cancer Combo Therapy in US
MT
08/24BEIGENE : Announces Acceptance of a Supplemental Biologics License Application in China fo..
PU
08/23BEIGENE : Says Chinese Regulator Accepts Supplemental Biologics License Application for Ca..
MT
08/23BeiGene Announces Acceptance of a Supplemental Biologics License Application in China f..
CI
08/22BEIGENE : Announces Acceptance of a Supplemental Biologics License Application in China fo..
BU
08/19BEIGENE : and EUSA Pharma Announce China NMPA Approval of QARZIBA« (Dinutuximab Beta) for ..
PU
08/18BEIGENE : and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for P..
AQ
08/18BEIGENE : Swiss Regulator Begins Review of BeiGene's Marketing Application for Lymphoma Dr..
MT
08/18BEIGENE : Announces Acceptance by Swissmedic of Marketing Authorization Application for BR..
BU
08/18BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for B..
CI
08/17BEIGENE : UK Partner's Cancer Drug Gets Conditional Approval in China
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BEIGENE, LTD.
11/11/21